secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001808805-22-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M
--------------------------------------------------------------------------------

- FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.
- Cash, equivalents, investments $362.1M as of Dec 31, 2021; raised ~$345.5M via SPAC merger in June 2021.
- Research collaborations with Amgen and MD Anderson; strategic partnership with Abcam for reagents.
- Platform commercialization targeted by end of 2023; published PrISM proteomics approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/0001808805-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/naut-20220224.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer